Your SlideShare is downloading. ×
5th Mayo Clinic Angiogenesis Symposium : Angiogenesis and Tumor Micro-enviroment: Basic Science to Clinical Practice
Upcoming SlideShare
Loading in...5

Thanks for flagging this SlideShare!

Oops! An error has occurred.


Saving this for later?

Get the SlideShare app to save on your phone or tablet. Read anywhere, anytime - even offline.

Text the download link to your phone

Standard text messaging rates apply

5th Mayo Clinic Angiogenesis Symposium : Angiogenesis and Tumor Micro-enviroment: Basic Science to Clinical Practice


Published on

  • Be the first to comment

  • Be the first to like this

No Downloads
Total Views
On Slideshare
From Embeds
Number of Embeds
Embeds 0
No embeds

Report content
Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

No notes for slide


  • 1. Alitalo Mayo School of Continuous Professional Development5th Mayo Clinic Angiogenesis Symposium:Angiogenesis and Tumor Micro-Environment:Basic Science to Clinical Practice August 17 - 19, 2012 17 - 19, 2012 2012 Depot Renaissance Hotel Minneapolis, Minnesota Course Director Debabrata Mukhopadhyay, Ph.D. Course Co-Director Neil Kay, M.D. Honorary Course Director i Philip Greipp, M.D.
  • 2. TABLE OF CONTENTSProgram Schedule ..........................................................................................................................iiCourse Description and Objectives..............................................................................................viiContinuing Education Credit ..................................................................................................... viiiFaculty...........................................................................................................................................ixFaculty Disclosure...................................................................................................................... xiiiEducational Grants .......................................................................................................................xvFriday, August 17, 20129:00 a.m. Registration10:00 a.m. Welcome and Introduction Philip Greipp, M.D. Debabrata Mukhopadhyay, Ph.D. Neil Kay, M.D.Folkman Lecture10:15 a.m. Regulation of the Angiogenic Switch David Cheresh, Ph.D.Section II: Mayo Clinic Lectureship Awards CeremonyChair: Debabrata Mukhopadhyay, Ph.D.10:45 a.m. Introduction if lectureship recipients and amount of lectureships Recipients: TBA11:15 p.m. Pre-Plenary Assessment Utilizing Audience ResponseSection III: Keynote LectureChair: Raghu Kalluri, M.D., Ph.D.11:25a.m. Angiogenesis and Lymphangiogenesis in Cancer and Cardiovascular Diseases Kari Alitalo, M.D., Ph.D.12:00 p.m. LunchSection IV: Regulation of AngiogenesisChair: Ramani Ramchandran, Ph.D.1:00 p.m. The Role of Sox and Robo’s in Angiogenesis Ramani Ramchandran, Ph.D. i
  • 3. 1:20 p.m. The Ins and Outs of Angiopoietin/Tie Signalling During Angiogenesis, Vascular Homeostasis and Tissue Regeneration Hellmut Augustin, Ph.D.1:40 p.m. Arteriogenic Signaling Cascade Timothy Hla, Ph.D.2:05 p.m. Molecular Mechanisms of Angiogenesis Michael Simons, M.D.2:30 p.m. Break2:50 p.m. Transcriptional Regulation of Vascular Endothelial Differention Saulius Sumanas, Ph.D.3:10 p.m. Mechanisms of Endothelial cell De-differentiation and Angiogenesis Kishore Wary, Ph.D.3:30 p.m. Epigenetic Regulation of Angiogenesis Mukesh Verma, Ph.D.3:50 p.m. Regulation of Angiogenesis and Metastasis by Thrombospondin-1 Jack Lawler,, Ph.D.4:10 p.m. Board buses for Blaisdell Manor5:00 p.m. Reception/Dinner Buffet/ Blaisdell Manor6:45 p.m. Plenary Lecture Chair: Sudipta Seal, Ph.D.7:00 p.m. Introducing New Nanotechnologies to Medicine Lodewyk Kock, Ph.D. Distinguished Professor: Microbial Biochemical and Food Biotechnology7:30 p.m. Adjourn to Social Hour9:00 p.m. Board buses to return to Depot RenaissanceSaturday, August 18, 21027:00 a.m. Continental Breakfast and RegistrationSection V: Angiogenesis and Vascular BiologyChair: Sundaram Ramakrishnan, Ph.D.8:00 a.m. Control of Vascular Tube Morphogenesis by Hematopoietic Stem Cell Cytokines George E. Davis, M.D., Ph.D.8:25 a.m. Interactions Between Tumor Cells and Lymphatic Endothelium in Cancer Progression Michael Detmar, M.D. ii
  • 4. 8:50 a.m. Vascular Permeability; VEGF and the Junction Lena Claesson-Welsh, Ph.D.9:10 a.m. Metabolic Stress, AMPK Cascades and Tumor Angiogenesis Kevin Claffey, Ph.D.9:30 a.m. In vitro and in vivo signaling mechanisms during endothelial tube formation Jeffrey Essner, Ph.D.9:50 a.m. BreakSection VI: Tumor MicroenvironmentChair: Suresh Mohla, Ph.D.10:10 a.m. How Can Resistance to Angiogenesis Inhibitors be Overcome? Donald M. McDonald, M.D., Ph.D.10:35 a.m. VEGF-dependent and -independent Angiogenesis Napoleone Ferrara , M.D. * *CME credit is not offered for this presentation.11:00 a.m. Tumor Microenvironment in Multiple Myeloma: The Role of Angiogenesis Sundaram Ramakrishnan, Ph.D.Section VII: Molecular Mechanisms of Angiogenesis and LymphangiogenesisChair: Nancy Emenaker, Ph.D., R.D.11:20 a.m. Cancer Stem Cells And Tumor Angiogenesis — Molecular Signaling And Therapeutic Targeting Suyun Huang, M.D., Ph.D.11:40 a.m. Fox Transcription Factors In Pathological Angiogenesis Tsutomu Kume, Ph.D.12:00 p.m. microRNA and Pancreatic Cancer Angiogenesis Keping Xie, M.D., Ph.D.12:20 p.m. LunchSection VIII: Angiogenesis and Cell SignalingChair: Yunling Gao, M.D., Ph.D.1:30 p.m. Dietary Modification of Pathological Angiogenesis Nancy Emenaker, Ph.D.., R.D.1:55 p.m. Novel Regulators of Vascular Function and Inflammation Tatiana V. Byzova, Ph.D.2:20 p.m. Regulation of CNS Angiogenesis Calvin Kuo, M.D., Ph.D. iii
  • 5. 2:45 p.m. Break3:10 p.m. Mechanisms by Which Pericyte Derived Myofibroblasts Regulate Tumor Growth Vijay Shah, M.D3:20 p.m. Mast Cell Mediated Neural Control of Angiogenesis Kalpna Gupta, Ph.D..3:40 p.m. Regulation of VEGFR2-mediated Vascular Permeability Suvro Chatterjee, Ph.D.Section IX: Mayo Clinic Travel Awards/Oral PresentationsChairs: Vijay Shah, M.D. and Philip Greipp, M.D.4:20 p.m. Poster Sessions/Reception6:00 p.m. Mayo Clinic Young Investigator Presentations7:00 p.m. Banquet/buffetSunday, August 19, 20127:00 a.m. Continental Breakfast and RegistrationSection XI: Angiogenesis in the Clinical SettingChair: Laura Benjamin, Ph.D.8:00 a.m. Angiogenesis Imaging in Neoplasia Sanjay Misra, M.D.8:20 a.m. Novel Designs and End Points for Phase II Clinical Trials Sudhakar Akulapalli, MSc., MPhill & Ph.D.8:40 a.m. The Reactive Oxygen Driven Tumor-Implications for Diagnosis and Treatment Jack Arbiser, M.D., Ph.D.9:00 a.m. Anti-Angiogenic Therapy: Clinical Challenges Debabrata Mukhopadhyay, Ph.D.9:20 a.m. The Myeloma Conundrum: Roadmap or Distraction for the Treatment of Cancer? S. Vincent Rajkumar, M.D.9:40 a.m. Anti-angiogenic Therapy in Melanoma Svetomir Markovic, M.D., Ph.D.10:00 a.m. Break iv
  • 6. 10:30 a.m. Adjuvant Hepatic Arterial Infusional Chemotherapy: Revisiting The Past or A New Era? Axel Grothey, M.D.10:50 a.m. Leukemic B Cell Interaction With Its Microenvironment: Implications for Therapy Neil Kay, M.D.Section XII: Mayo Clinic LectureshipChair: Philip Greipp, M.D.11:10 a.m. Introduction11:20 a.m. TBA Shaji Kumar, M.D.11:50 a.m. The Role of Angiogenesis Inhibitors in Central Nervous System Tumors Jan Buckner, M.D12:20 p.m. Closing Comments and Adjourn Debabrata Mukhopadhyay, Ph.D. v
  • 7. Course DescriptionThe main goal of our symposium is to bring together basic science and clinical experts in the fieldof angiogenesis to facilitate the exchange of ideas and science involving basic biology andpathways of angiogenesis and new anti-angiogenic agents that can be used for specific targetingof tumor blood vessels and stroma. Moreover, the clinician scientists will present the results ofongoing clinical trials on anti-angiogenic therapy. Novel genetic and imaging methods to assesstumor vasculature for monitoring the effectiveness of angiogenic response in the pre-clinical andclinical trials will be discussed in this symposium. Overall, the symposium will assist inestablishing strong collaborations among leading national, international, and Mayo Clinic expertsin the field.Course ObjectivesUpon completion of this program, participants should be able to: • Critically assess the role of angiogenesis in different pathological situations. • Analyze the molecular pathways in angiogenesis. • Identify the importance of angiogenesis in cancer progression and metastasis. • Evaluate angiogenesis as a potential target for future cancer therapy. • Establish the therapeutic potential of anti-angiogenic molecules and translate basic science to clinical applications. • Build a collaborative platform where basic scientists and clinicians can interface.Intended Audience • Clinicians involved in cancer-related practice or research • Laboratory scientists • Translational researchers • Industry partners • Graduate or medical students • Postdoctoral fellows or residents • Others with an interest or with backgrounds in cardiovascular biology and developmental biology, myeloma, cancer, angiogenesis and related clinical trials, lymph angiogenesis, extracellular matrix, and anti-angiogenic therapy in differential tumors. vi
  • 8. Continuing Education CreditCollege of Medicine, Mayo Clinic, is accredited by the Accreditation Council for ContinuingMedical Education (ACCME) to provide continuing medical education for physicians.College of Medicine, Mayo Clinic, designates this live activity for a maximum of 18 AMA PRACategory 1 Credit™. Physicians should claim only the credit commensurate with the extent oftheir participation in the activity.Physicians should only claim credit commensurate with theextent of their participation in the activity.Other health care professionals will be provided a certificate of attendance for requesting creditsin accordance with state nursing boards, specialty societies, or other professional associations.CME Record of AttendanceA Record of Attendance is provided to you during on-site registration. The Record of Attendanceallows course attendees to calculate their own credits of participation in the educational activity.The total number of credits participants can earn per day is noted on the Record of Attendance.Below each day is a line to record the actual number of credits during which you participated inthe educational activity. It is recommended that you record your actual credits daily as youproceed through the course.Upon conclusion of the course, please total the number of credits you have recorded on the tophalf of the form, sign it, and return to the registration desk.The bottom half of the form represents your Record of Attendance, which you must retain for yourrecords. Please make sure the number of credits claimed in both sections coincide.Course EvaluationA course evaluation form will be emailed to you post course. Please complete and return theevaluation electronically. Your feedback is very important to us and will be used for planningfuture programs.Smoking PolicyIn keeping with Mayo Clinic policy, smoking is not permitted in any of the meeting rooms orcourse facilities during Mayo-sponsored activities.Taping of SessionsAudio or visual taping by participants is not permitted. vii
  • 9. Electronic DevicesAs a courtesy to other attendees, please turn off or place in silent mode all cell phones, pagers,PDA’s, laptop computers, etc.DisclaimerThe material presented in this continuing medical education program is made available by theCollege of Medicine, Mayo Clinic, for educational purposes only. This material is not intended torepresent the only, or necessarily the best, methods or procedures appropriate for the medicalsituation discussed, but rather is intended to present an approach, view, statement or opinion ofthe authors or presenters that may be helpful or of interest to other practitioners. As an attendee,you agree to participate in this medical education program sponsored by the College of Medicinewith full knowledge and awareness that you waive any claim you may have against the College ofMedicine or Mayo Clinic for reliance on any information presented in this educational program.The approval of the U.S. Food and Drug Administration is required for procedures and drugs thatare considered experimental. Instrumentation systems discussed and/or demonstrated in or at thisprogram may not yet have received FDA approval.All of the proceedings of this program, including the presentation of scientific papers, areintended for limited publication only, and all property rights in the material presented, includingcommon-law copyright, are expressly reserved by the speaker, the College of Medicine or MayoClinic. No statement of presentation made is to be regarded as dedicated to the public domain.Any sound reproduction, transcript or other use of the material presented at this course withoutthe permission of the College of Medicine is prohibited to the full extent of common-lawcopyright in such material.Attendance at this Mayo course does not indicate nor guarantee competence or proficiency in theperformance of any procedures that may be discussed or taught in this course.FACULTYProgram DirectorsDebabrata Mukhopadhyay, Ph.D., Mayo Philip R. Greipp, M.D., Mayo Clinic,Clinic, Department of Biochemistry & Department of Hematology, HematologyMolecular Biology ResearchProgram ChairpersonNeil E. Kay, M.D., Mayo Clinic,Department of Hematology viii
  • 10. Program Planning CommitteePhilip R. Greipp, M.D. Debabrata Mukhopadhyay, Ph.D.Mayo Clinic Mayo ClinicDepartment of Hematology Department of Biochemistry &Hematology Research Molecular BiologyKalpna Gupta, Ph.D. Sundaram Ramakrishnan, Ph.D.Medicine – Hematology, Oncology and PharmacologyTransplantation Office University of MinnesotaUniversity of Minnesota Vijay H. Shah, M.D.Neil E. Kay, M.D. Mayo ClinicMayo Clinic Department of Gastroenterology/GIDepartment of Hematology Basic Research CenterMayo Clinic FacultyJan Buckner, M.D. Sanjay Misra, Ph.D.Philip R. Greipp, M.D. Debabrata Mukhopadhyay, Ph.D.Axel Grothey, M.D. S. Vincent Rajkumar, M.D.Neil E. Kay, M.D. Vijay H. Shah, M.D.Shaji Kumar, M.D.Svetomir Markovic, M.D., Ph.D.Guest FacultyKari Alitalo, M.D., Ph.D. Suvro Chatterjee, Ph.D.University of Helsinki, Finland KBC Research Center Anna University, IndiaJack Arbiser, M.D., Ph.D.Emory University, School of Medicine David Cheresh, Ph.D.Winship Cancer Institute Moores UCSD Cancer CenterHellmut Augustin, Ph.D. Lena Claesson-Welsh, Ph.D.German Cancer Research Center and Uppsala University, SwedenHeidelberg University Kevin Claffey, Ph.D.Tatiana V. Byzova, Ph.D. Center for Vascular BiologyDept. of Molecular Cardiology UCONN Health CenterCleveland Clinic Foundation ix
  • 11. George Davis, Ph.D. Calvin Kuo, M.D., Ph.D.Medical Pharmacology/Physiology Stanford UniversityUniversity of Missouri Jack Lawler, Ph.D.Michael Detmar, M.D. Beth Israel Deaconess Medical CenterSwiss Federal Institute of Technology Harvard Medical SchoolZurich, Switzerland Donald McDonald, M.D., Ph.D.Nancy Emenaker, Ph.D., R.D. University of CaliforniaNutritional Science Research Group San Francisco Medical CenterDivision of Cancer PreventionNational Cancer Institute Suresh Mohla, Ph.D. Division of Cancer Biology, NCIJeffrey Essner, Ph.D.Department of Genetics Ramani Ramchandran, Ph.D.Iowa State University Medical College of WisconsinNapoleone Ferrara, M.D. Sudipta Seal, Ph.D.Genentech, Inc. The University of Texas M.D. Anderson CancerYunling Gao, M.D., Ph.D.Division of Cardiovascular Sciences Saulius Sumanas, Ph.D.NHLBI, NIH Developmental Biology Cincinnati Children’s HospitalTimothy Hla, Ph.D. Medical CenterWeill Cornell Medical College Michael Simons, M.D.Suyun Huang, M.D., Ph.D. Yale UniversityThe University of TexasM.D. Anderson Cancer Center Kishore Wary, Ph.D. Department of PharmacologyLuisa Iruela-Arispe, Ph.D. University of IllinoisDept. of Molecular, Cell Developmental Biology Mukesh Verma, Ph.D.UCLA Epidemiology and Genomics Research National Cancer InstituteRaghu Kalluri, M.D., Ph.D.Harvard Medical School Keping Xie, M.D., Ph.D. The University of TexasLodewyk Kock, Ph.D. M.D. Anderson Cancer CenterUniversity of the Free StateSouth Africa Sudhakar Akul Yakkanti, Ph.D. University of Nebraska Medical CenterTsutomu Kume, Ph.D.Northwestern University xii
  • 12. DISCLOSURE SUMMARY TO CME PARTICIPANTSAs a provider accredited by ACCME, Mayo School of Continuing ProfessionalDevelopment must ensure balance, independence, objectivity and scientific rigor in itseducational activities. Course Director(s), Planning Committee Members, Faculty, andall others who are in a position to control the content of this educational activity arerequired to disclose all relevant financial relationships with any commercial interestrelated to the subject matter of the educational activity. Safeguards against commercialbias have been put in place. Faculty also will disclose any off label and/or investigationaluse of pharmaceuticals or instruments discussed in their presentation. Disclosure of thisinformation will be published in course materials so those participants in the activity mayformulate their own judgments regarding the presentation. Listed below are individuals with control of the content of this program who have disclosed… Relevant financial relationship(s) with industry:Kari Alitalo, M.D., Ph.D. Circadian Technologies, Ltd. Chairman Vegenics, Ltd.Jack Arbiser, M.D., Ph.D. Naturderm Stock Shareholder Allmera HonorariaHellmut Augustin, Ph.D. Bayer-Schering Pharma Grant/Research SupportLaura Benjamin, Ph.D. Eli Lilly & Co. Full/part-time employeeDavid Cheresh, Ph.D. Targegen, Inc., Kinagen, Inc. Consultant Targegen, Inc., Kinagen, Inc. Stock ShareholderNapoleone Ferrara, M.D. Genetech, Inc. Full/part-time employeeNeil E. Kay, M.D. Celgene Consultant Celgene, Callstoga, Cephalon, Genetech, GlaxoSmithKline, Hospira, Novartis, Rigel, Trubion Grant/Research SupportShaji Kumar, M.D. Celgene, Millenium, Genzyme, Novartis Grant/Research SupportCalvin Kuo, M.D., Ph.D. NIH Grant/Research SupportDonald McDonald, M.D. Pfizer, Exelexis, OSI, Medimmuna Grant/Research SupportSudipta Seal, Ph.D. NSF, NIH Grant/Research SupportSimons, Michael, M.D. AnGes, Inc. Consultant xiii
  • 13. No relevant financial relationship(s) with industry:Alex Adjei, M.D., Ph.D. Raghu Kalluri, Ph.D.Colleen Allen Lodewyk Kock, Ph.D.Jan Buckner, M.D. Christopher Kontos, M.D.Tatiana V. Byzova, Ph.D. Jack Lawler, Ph.D.Suvro Chatterjee, Ph.D. Denise LecyLena Claesson-Welsh, Ph.D. Svetomir Markovic, M.D., Ph.D.Kevin Claffey, Ph.D. Sanjay Misra, M.D.George Davis, M.D., Ph.D. Suresh Mohla, Ph.D.Michael Detmar, M.D. Debabrata Mukhopadhyay, Ph.D.Nancy Emanker, Ph.D., R.D. Ramani Ramchandran, Ph.D.Jeffrey Essner, Ph.D. Sundaram Ramakrishnan, Ph.D.Yunling Gao, M.D., Ph.D. Saulius Sumanas Ph.D.Axel Grothey, M.D. Vijay H. Shah, M.D.Kalpna Gupta, Ph.D. Kishore Wary, Ph.D.Timothy Hla, Ph.D. Mukesh Verma, Ph.D.Suyun Huang, M.D. Keping Xie, Ph.D.Luisa Iruela-Arispe, Ph.D. Sudhakar Akulapalli, Ph.DReferences to off-label usage(s) of pharmaceuticals or instruments in their presentation:Napoleone Ferrara, M.D. Genentech BevacizumabPhilip R. Greipp, M.D. Celgene R&TS. Vincent Rajkumar, M.D. Celgene Lenalidomide, Pomalidomide xiv
  • 14. This course is supported in part by unrestricted educational grants from the following companies in accordance with ACCME standards: Lilly USA, LLC Millennium Sanofi-Aventis TEVA xv